Abstract:Histone deacetylases (HDACs) are a superfamily of enzymes that catalyze the removal of acetyl functional groups from lysine residues of histone and non-histone proteins. There are 18 mammalian HDACs, which are classified into four classes based on the primary homology with yeast HDACs. Among these groups, Class I and II HDACs play a major role in lysine deacetylation of the N-terminal histone tails. In mammals, HDACs play a pivotal role in the regulation of gene transcription, cell growth, survival, and proliferation. HDACs regulate the expression of inflammatory genes, as evidenced by the potent anti-inflammatory activity of pan-HDAC inhibitors, which were implicated in several pathophysiologic states in the inflammation process. However, it is unclear how each of the 18 HDAC proteins specifically contributes to the inflammatory gene expression. It is firmly established that inflammation and its inability to converge are central mechanisms in the pathogenesis of several cardiovascular diseases (CVDs). Emerging evidence supports the hypothesis that several different pro-inflammatory cytokines regulated by HDACs are associated with various CVDs. Based on this hypothesis, the potential for the treatment of CVDs with HDAC inhibitors has recently begun to attract attention. In this review, we will briefly discuss (1) pathophysiology of inflammation in cardiovascular disease, (2) the function of HDACs in the regulation of atherosclerosis and cardiovascular diseases, and (3) the possible therapeutic implications of HDAC inhibitors in cardiovascular diseases. Recent studies reveal that histone deacetylase contributes critically to mediating the pathophysiology of inflammation in cardiovascular disease. HDACs are also recognized as one of the major mechanisms in the regulation of inflammation and cardiovascular function. HDACs show promise in developing potential therapeutic implications of HDAC inhibitors in cardiovascular and inflammatory diseases.

Research progress of HDACs and associated inhibitors on regulation of acute lung injury

The Role of Histone Deacetylases in Acute Lung Injury—Friend or Foe

Classical HDACs in the Regulation of Neuroinflammation.

The involvement of HDAC3 in the pathogenesis of lung injury and pulmonary fibrosis

Update and Ralated Researches in Treatment with Histone Deacetylase Inhibitors Against Hemorrhagic Shock

HDACi: molecular mechanisms and therapeutic implications in the innate immune system

Progress in the Mechanism and Therapy Research of ALI/ARDS

Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis Via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.

Research progress of signaling pathways in acute lung injury

Histone deacetylases and their inhibitors in inflammatory diseases

Research Progress on the Role of Extracellular Histones in Acute Respiratory Distress Syndrome

Research Progress on Attenuating ALI by the Inhibition of HIF-1α Pathway

A comparative analysis to determine the optimum histone deacetylase inhibitors and administration route for improving survival and organ injury in rats after hemorrhagic shock

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis

HDAC3 deficiency protects against acute lung injury by maintaining epithelial barrier integrity through preserving mitochondrial quality control

Pro-resolution of Inflammation: a Potential Strategy for Treatment of Acute Lung Injury/acute Respiratory Distress Syndrome.

The role of histone deacetylases in inflammatory respiratory diseases: an update

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

HDAC3 Promotes Macrophage Pyroptosis Via Regulating Histone Deacetylation in Acute Lung Injury

Hypoxia-Inducible Factor-1: A Potential Target to Treat Acute Lung Injury

Critical Functions of Histone Deacetylases (HDACs) in Modulating Inflammation Associated with Cardiovascular Diseases